Licochalcone A from licorice reprograms metabolic and antioxidant pathways in the breast leading to a tumor preventive environment.

Atieh Hajirahimkhan¹, Elizabeth T. Bartom², Sriram Chndrasekaran³, Susan E. Clare¹, Seema A. Khan¹
¹Division of Breast Surgery, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, ²The Louis A. Simpson and Kimberly K. Querrey Biomedical Research Center, Northwestern University, Chicago, IL. ³Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI.

**BACKGROUND**

- Less than 5% of women who could benefit from breast cancer risk reduction drugs report taking them, mainly due to the adverse effects of these medications.
- Prevention strategies with optimal efficacy, less toxicity, and greater acceptance are needed.
- Natural products with significantly low toxicity and sufficient efficacy to shift the breast microenvironment to a tumor preventive milieu are ideal candidates.
- Previously, we have shown that licochalcone A (LicA) from licorice inhibits aromatase activity and has antioxidant potential.
- We now report on the response of high-risk postmenopausal human breast tissue and breast pre-malignant and malignant cells to LicA treatment in vitro.

**OBJECTIVE**

We hypothesize that LicA modulates metabolic and antioxidant pathways in the breast leading to a tumor preventive environment.

**METHODS**

- Contralateral unaffected breast tissue of 6 postmenopausal women, who had bilateral mastectomy due to unilateral breast cancer were obtained and processed to microstructures which maintain the architectural features and protein expression patterns of the tissues of origin.
- Microstructures were treated with DMSO and LicA (5 μM) for 24 h, prior to RNA extraction and total RNA sequencing.
- Differential gene expression was determined. Gene ontology (GO) pathway analysis was performed. The enriched pathways with combined enrichment scores > 4 and FDR < 0.05 were considered statistically significant. We performed live cell imaging/proliferation on DCIS.COM/ER+ PR+, DCIS.COM, MCF-7, and MDA-MB-231 cells treated with various doses of LicA.

**RESULTS**

- **LicA retards proliferation in malignant breast cell lines.**
  - Live cell imaging using IncuCyte showed that a single dose of LicA can retard proliferation of (A) MCF-7 and (B) MDA-MB-231 cells.

- **Computational Metabolic Flux analysis showed increased flux through pathways leading to enhanced NADPH production (P < 0.05).**
  - Metabolic flux analysis supports antioxidant and anti-adipogenic effects.

- **Pathways**
  - One Carbon Metabolism
  - Cholesterol Homeostasis, (PPP)
  - Pentose Phosphate Pathway, (PPP)
  - Cholesterol Biosynthesis
  - Fatty Acid Synthesis
  - NADPH Antioxidant/Anti-inflammation Pathways
  - Cell death

- **Gene Ontology: biological process**

  The scatterplot is organized so that similar gene sets are clustered together. Larger, black-outlined points represent significantly enriched terms.

**REFERENCES**


**Supported by the American Cancer Society postdoctoral fellowship 131667-PF-18-049-01NEC. NIH grant P50 AT00155 provided by ODS and NCCIR, and by Bramson-Hamill Foundation.**

Copies of this poster may not be reproduced without permission from the author of this poster. Contact them at atieh.hajirahimkhan@northwestern.edu for permission to reprint and/or distribute.